Abstract Obstructive sleep apnea (OSA) and hypertension are closely linked conditions. Disordered breathing events in OSA are characterized by increasing efforts against an occluded airway while asleep, resulting in a marked sympathetic response. This is predominantly due to hypoxemia activating the chemoreflexes, resulting in reflex increases in sympathetic neural outflow. In addition, apnea -and the consequent lack of inhibition of the sympathetic system that occurs with lung inflation during normal breathing -potentiates central sympathetic outflow. Sympathetic activation persists into the daytime, and is thought to contribute to hypertension and other adverse cardiovascular outcomes. This review discusses chemoreflex physiology and sympathetic modulation during normal sleep, as well as the sympathetic dysregulation seen in OSA, its extension into wakefulness, and changes after treatment. Evidence supporting the role of the peripheral chemoreflex in the sympathetic dysregulation seen in OSA, including in the context of comorbid obesity, metabolic syndrome, and systemic hypertension, is reviewed. Finally, alterations in cardiovascular variability and other potential mechanisms that may play a role in the autonomic imbalance in OSA are also discussed.
Introduction
Obstructive sleep apnea (OSA) is a common condition. Recent community studies estimate that 10-17 % of males and 3-9 % of females aged 30-70 years have moderate to severe sleep apnea [1] , with a significant increase in prevalence within the last two decades [1] . OSA is characterized by collapse of the upper airway that occurs in a repetitive fashion throughout sleep, leading to sleep disruption, daytime sleepiness, and increased risk of workplace and motor vehicle accidents. OSA has also been associated with a number of adverse cardiovascular consequences, including hypertension, coronary artery disease, stroke, both systolic and diastolic heart failure, and arrhythmias [2] [3] [4] [5] [6] [7] [8] [9] . Of these, the link between OSA and systemic hypertension is the most welldefined, with several population-based studies demonstrating an increased incidence of baseline and future hypertension in subjects with OSA [10] [11] [12] [13] . This is an important issue for clinicians treating patients with hypertension, as approximately 50 % of these patients have comorbid OSA [14] , which is a readily treatable condition [15] , and there is a dose-response relationship between severity of untreated OSA and the incidence of hypertension [12, 16] . In addition, OSA appears to be the most common secondary cause of elevated blood pressure (BP) in individuals with resistant hypertension [14] .
The mechanisms underlying the increased risk of hypertension and other adverse cardiovascular effects in OSA are not fully understood. The relative contribution of obesity versus OSA to the overall increased risk is especially unclear [17, 18•] . There is a growing body of evidence to suggest that autonomic dysfunction, specifically altered chemoreflex control of sympathetic activity, may play a prominent role in this relationship [19, 20•, 21] .
In this review, we discuss normal chemoreflex control of sympathetic activity and how this is altered in the setting of OSA, both in sleep and wakefulness, as well as in the treated OSA patient. We discuss the relationship between the resulting sympathetic dysregulation in OSA and disorders of obesity, metabolic syndrome, and particularly hypertension. Other possible mechanisms contributing to sympathetic dysregulation in the setting of OSA are also described. For purposes of this review, the term "sleep apnea" refers to OSA. Autonomic dysfunction pertaining to central sleep apnea (CSA), seen frequently in patients with heart failure, is beyond the scope of this review. In addition, this discussion is limited to studies involving adult subjects.
The Chemoreflexes
The chemoreflexes include central chemoreceptors in the brainstem and peripheral chemoreceptors in the carotid bodies located near the internal carotid arteries. The central chemoreceptors respond mainly to hypercapnia, whereas the peripheral chemoreceptors respond primarily to hypoxia. There have been recent advances in the understanding of the molecular mechanisms involved in the functioning of the peripheral carotid chemoreceptors [22•, 23•, 24, 25] . While hypoxic and/or hypercapnic chemoreflex activation elicits increases in central sympathetic outflow, it also stimulates hyperventilation, which inhibits sympathetic activity [26•, 27•, 28]. The peripheral chemoreceptors responding to hypoxia appear to be more influenced by this inhibition, perhaps due to the thoracic afferents and afferents from peripheral chemoreceptors synapsing close to the nucleus tractus solitarii in the brainstem [29•, 30] .
The chemoreflexes play an important role in the control of ventilation, and activation of the chemoreflex causes hyperventilation. They also play a significant role in cardiovascular control, with activation resulting in increased BP due to sympathetic activation [31] [32] [33] . Chemoreflex control of breathing and of cardiovascular systems are closely linked, such that when there is an increase in ventilation, chemoreflex-mediated cardiovascular responses are attenuated due to stretch of the thoracic afferents [26•, 27•, 34•]. There is also a negative feedback mechanism operating within the cardiovascular system, wherein chemoreflex-induced activation of the cardiovascular system results in increased BP that activates the arterial baroreceptors, which in turn serves to attenuate the chemoreflex response [28, 32, 35] . This mechanism is more prominent for responses mediated by hypoxia than by hypercapnia [28] .
When an apnea occurs, hypoxia and/or hypercapnia without accompanying increase in ventilation activate the peripheral chemoreflex, which results in marked sympathetic activation of blood vessels in the musculature, causing vasoconstriction. In other words, sympathoexcitation is unopposed in the face of lack of inhibition from normal ventilation. The peripheral chemoreflex also simultaneously increases vagal activity to the heart. Thus, the so-called diving reflex is activated, whereby apnea and hypoxia result in peripheral vasoconstriction and bradycardia [36] [37] [38] . These responses may explain the mechanisms that mediate increased risk of hypertension and other adverse cardiovascular consequences in OSA patients.
Sympathetic Activity in Normal Sleep

NREM Sleep
The alterations in ventilation, heart rate (HR), and BP that occur in normal sleep are predominantly sleep-stagedependent [39, 40•], and are mediated by modifications in autonomic control [40•] . There is a progressive reduction in central respiratory drive, minute ventilation, and PaO2, accompanied by a rise in PaCO2 in non-rapid eye movement (NREM), in sleep stages 1 through 3. There is a simultaneous increase in parasympathetic tone and decrease in sympathetic activity such that HR, BP, stroke volume, and systemic vascular resistance all show a decline [40•, 41].
Arousals
Arousals from sleep are associated with abrupt increases in both respiratory and cardiovascular activity [42, 43] , and the augmentation of ventilatory drive that occurs is above what would be expected for the given PaCO2 level [43] . At the same time, there is an increase in sympathetic activity and a decrease in cardiac vagal activity exceeding normal wakefulness levels, causing significant surges in HR and BP [42] . One study suggested the presence of long-lasting sympathetic activation in normal subjects exposed to repetitive arousals from sleep [44] , potentially predisposing to the development of hypertension. Furthermore, an increased number of arousals are seen in the context of recurrent respiratory events in patients with OSA.
REM Sleep
The chemoreflexes appear to play a less important role in rapid-eye-movement (REM) sleep [39, 45] . Atonia of the respiratory muscles, excluding the diaphragm, and a reduction in chemosensitivity both occur in REM [39] , and the combination of these two factors results in an increase in PaCO2 and decrease in ventilation to levels lower than that seen in NREM sleep. In contrast, HR, BP, and sympathetic nerve activity increase to levels similar to those in wakefulness [40•].
Sympathetic Activity in OSA
During Sleep
In patients with OSA, sympathetic activity and cardiovascular parameters during sleep depend upon the severity and duration of the apnea rather than sleep stage. Repetitive episodes of apnea and hypoxia in sleep result in activation of the chemoreceptor reflex and increased sympathetic activation [34•]. Once breathing resumes, venous return and cardiac output increase, but the increased cardiac output is delivered into a highly constricted peripheral vasculature, resulting in surges in BP as high as 250/110 mm Hg at the end of an apnea [34•, 46, 47] . It is thought that the phenomenon of "nondipping" of BP at night in many individuals, which is linked to increased risk of adverse cardiovascular consequences [48] , may in fact arise as a result of undiagnosed sleep apnea causing surges in BP [49, 50] . There is a high prevalence of sleep apnea in hypertensive patients who do not experience nocturnal blood pressure reduction, and thus the non-dipping phenomenon could be considered a simple indirect clinical marker of increased risk of sleep apnea.
During Wakefulness
Higher levels of sympathetic activity in subjects with OSA are noted even during wakefulness, when they are breathing normally. The study of sympathetic nerve activity has become easier with the advent of microneurography, which permits direct intraneural measurement of sympathetic nerve traffic. Studies in humans have shown increased muscle sympathetic nerve activity (MSNA) under hypoxic conditions at simulated altitudes [51] . This increased activity has been known to persist even after removal from acute short-term exposure to intermittent hypoxia [52] [53] [54] [55] [56] [57] .
In both animal [58] [59] [60] and human studies [61] , increased sympathetic nerve activity and mean arterial BP have been found not only with acute intermittent hypoxia but with chronic intermittent hypoxia as well. Both acute and chronic intermittent hypoxia appear to be more potent in inducing this sympathoexcitatory response than sustained hypoxia, at least in rodent studies [62] .
In rat models, intermittent hypoxia has been demonstrated to increase circulating catecholamines [63, 64] and sympathetic nerve activity [56] , which appears to be mediated by enhanced acute hypoxia sensing via formation of reactive oxygen species [65, 66] . This effect also appears to be independent of respiratory drive [57] , and correlates with increased expiratory activity [60] . Caution should be exercised in extrapolating these results to human subjects.
Studies in humans have also revealed increased daytime urinary noradrenaline levels [67] [68] [69] and increased sympathetic nerve activity in subjects exposed to intermittent hypoxia under experimental conditions [70] . A handful of studies have revealed increased sympathetic activity in human subjects with OSA during wakefulness under conditions of normoxia; this was true regardless of whether subjects were on antihypertensive therapy [34•, 71, 72] . One study demonstrated that hyperoxia reduced HR, BP and MSNA in human subjects with OSA but not in controls [73] , and similar findings have been noted by other researchers [74] . Together, these studies reflect increased sympathetic activity in the setting of intermittent hypoxia in both animals and humans.
The sympathoexcitatory response appears to be more sensitive to hypoxia than to hypercapnia as the stimulus [54, 75] , although apnea and hypercapnia may contribute and, in fact, act synergistically to elicit the overall response [26•, 71, 76, 77] .
In one recent study of healthy human subjects, increased MSNA was shown to be independently associated with pulse wave velocity, a powerful predictor of cardiovascular morbidity and mortality [78] . Further research is needed to confirm these findings in patients with OSA.
In summary, patients with OSA tend to have acute and chronic intermittent hypoxia during sleep. Sustained hypoxia or hypercapnia in the setting of OSA without comorbid respiratory or neuromuscular conditions and/or obesity hypoventilation syndrome is rare. Both acute and chronic intermittent hypoxia are powerful stimuli for the sympathetic activation seen during sleep and wakefulness in subjects with OSA.
Sympathetic Activity in Treated OSA Patients
Treatment of OSA with tracheostomy has been shown to reduce nighttime urinary catecholamine and daytime MSNA [68] . Continuous positive airway pressure (CPAP), the therapy most commonly used for OSA, has been noted to result in decreased sympathetic activity and attenuated BP surges in sleep [34•]. In addition, CPAP has been shown to lower MSNA after six months and one year of treatment in treated compared to untreated OSA patients [79, 80•] , and this effect is greatest in those with the highest number of hours of CPAP usage [81, 82] . Reduction in sympathetic activity with CPAP, measured by urinary noradrenaline levels, appears to be more prominent in patients with severe OSA [83] and those with diabetes mellitus [84] .
Long-term CPAP treatment has also been shown to decrease BP, particularly 24-hour BP, in prehypertensive [85, 86] and hypertensive OSA patients [84, [87] [88] [89] [90] [91] . A similar decline in 24-hour mean BP has been noted with oral appliance treatment for OSA as well [92] . However, several metaanalyses show only very modest blood pressure lowering effects, around 2 mmHg [89, 91] . Interestingly, CPAP therapy has been shown by some investigators to decrease the risk of incident new hypertension [12] , whereas others have reported no significant effect [93] .
A recent study performed in a cohort of subjects with resistant hypertension demonstrated significant reduction in 24-hour mean and diastolic BP after 12 weeks in patients receiving CPAP treatment compared to those who did not receive therapy. The percentage of patients displaying a nocturnal dipping pattern was higher in the CPAP versus the no-CPAP group [94] .
There appears to be an interaction between sleepiness and BP response to CPAP treatment in OSA patients. Some studies have shown no significant BP reduction after CPAP in the absence of sleepiness [93, 95, 96] or an enhanced response in patients who are sleepy [88] .
Role of the Chemoreflex in Sympathetic Dysregulation Seen in OSA
It is clear that OSA is associated with a state of sympathetic dysregulation, and the mechanisms leading to this dysregulation have been the focus of a number of studies. The chemoreflex is thought to play an important role [20•, 26 •, 27•, [97] [98] [99] [100] [101] , although other mechanisms may contribute, as described below. Animal studies have indicated that the peripheral chemoreceptors located in the carotid body play a pivotal role in the response to hypoxia in OSA [102] [103] [104] [105] [106] [107] [108] [109] . More recent analyses have demonstrated differential expression of the various hypoxia-inducible factor (HIF) subtypes in the carotid body associated with local inflammation [110] [111] [112] . In the future, functional neuroanatomic imaging studies of the carotid bodies may provide more insight into the exact pathologic processes involved [113] .
Several studies have determined that increased peripheral chemoreflex sensitivity [97, 103, [114] [115] [116] and tonic activation [29•, 54, 72, 117] of the peripheral chemoreceptors, even during normoxia, are mechanisms that may explain the observed increased sympathetic activity during wakefulness in OSA.
It is not entirely clear whether healthy human subjects experience sympathetic dysregulation in response to intermittent hypoxia. One study revealed increased pressor and cerebrovascular resistance responses in healthy subjects exposed to intermittent hypoxia [118] . Another study showed increased MSNA with voluntary apnea in trained divers but not in controls [119] . Other studies, however, have noted no significant differences in autonomic measures between trained healthy divers and controls at rest, suggesting that while sympathetic dysregulation in response to hypoxia occurs in OSA, it is generally not seen with voluntary apnea training in healthy subjects [120, 121] . Nevertheless, it is evident that the chemoreflex-induced sympathetic response to hypoxia is exaggerated in OSA compared to subjects without OSA who are exposed to hypoxia. There appears to a blunting of this effect with recurrent apneas, at least in animal studies [122] , leading one to infer that the exaggerated chemoreflex is a pathophysiologic characteristic rather than a consequence of OSA.
Relationship with Obesity
Whether obesity plays an intermediary or supplementary role in the relationship between OSA and autonomic imbalance is not fully known. Sympathoexcitation has been observed in OSA patients as a response to apnea with associated hypoxia, and is more marked than in weight-matched controls without OSA experiencing a similar level of induced hypoxia [71, 73] . Similarly, increased MSNA has been detected in subjects with OSA compared to obese and normal-weight non-OSA subjects, with both of the latter two demonstrating fairly similar levels of sympathetic activity [73] . These results suggest that the enhanced sympathetic drive in OSA, as well as any underlying chemoreflex mechanism, is likely not related to obesity per se.
Relationship with Metabolic Syndrome
OSA and metabolic syndrome are frequently comorbid conditions, and it appears that OSA may worsen the sympathetic dysregulation already present in patients with metabolic syndrome. One study showed higher MSNA in subjects with metabolic syndrome and OSA compared to both those with metabolic syndrome without OSA and healthy controls. Overall, in the patients with metabolic syndrome, MSNA was significantly associated with severity of OSA, as assessed by the apnea-hypopnea index (AHI), after accounting for confounders [123] . Another study showed that baseline MSNA was higher in subjects with both OSA and metabolic syndrome compared to those with OSA without metabolic syndrome, which in turn was higher than that observed in healthy controls. Increased MSNA in response to isocapnic hypoxia was also greater in patients with OSA plus metabolic syndrome compared to the other two groups. OSA in this study was defined as an AHI of equal to or greater than 15 per hour [124] .
Relationship with Hypertension
OSA is tightly linked to hypertension, and the chemoreflex has been implicated as a possible major contributor. Canine studies have shown a sustained increase in daytime BP related to repeated airway occlusion, although this is not seen if there were repeated awakenings without airway manipulation [125] . Several studies in rodents have demonstrated increased arterial BP in response to intermittent hypoxia [22•, 100, 115, 126], but not with hypercapnia. In one study of human subjects with OSA, the sympathetic response to hypoxia was found to be related to AHI and nocturnal urinary adrenaline levels, and was independently associated with increased diurnal and nocturnal mean BP [117] . Taken together, these results suggest a possible mediating role of peripheral chemosensitivity in the relationship between OSA and hypertension.
Interestingly, the increased peripheral chemoreflex response to hypoxia that occurs in normotensive sleep apnea patients [72] is seen in patients with mild hypertension as well [127] , t h e r e f o r e s u g g e s t i n g s o m e s i m i l a r i t i e s i n t h e sympathoexcitatory response between normotensive subjects with OSA and those with early mild hypertension [18•, 29•, 62] . Previous studies have demonstrated increased MSNA in subjects with mild hypertension [128] [129] [130] related to nighttime and daytime HR but not to the morning surge in BP [131] . Autopsy studies in hypertensive humans have also shown morphologic abnormalities in the carotid bodies [132] [133] [134] .
In summary, there appears to be an association among abnormalities in the carotid body, sympathetic dysregulation, and hypertension, although it is not completely clear whether these changes precede or occur as a result of hypertension. In one study of rats, exposure to chronic intermittent hypoxia produced a shift in the HR variability power spectrum reflecting a predominance of sympathetic modulation at 14 days, but arterial BP did not increase until day 21 of exposure [135] . These data suggest that changes in autonomic balance may precede the development of hypertension induced by chronic intermittent hypoxia, and further studies are needed to corroborate these findings in human subjects with OSA.
Cardiovascular Variability
During wakefulness, OSA patients demonstrate evidence not only of increased sympathetic activity, but also abnormalities of cardiovascular variability, another reflection of the autonomic dysfunction that occurs in this group [136] . These abnormalities include greatly increased BP variability and decreased R-R variability, occurring in a dose-response fashion with the severity of OSA, even in the absence of hypertension [136] [137] [138] . Treatment with CPAP has been shown to normalize HR variability indices both acutely and chronically [139, 140] .
A recent study demonstrated changes in HR variability that suggested a reduction in cardiac vagal modulation in subjects with asymptomatic OSA compared to obese controls [141] , reflecting a decrease in parasympathetic activity and an increase in sympathetic activity in OSA patients, opposite to that noted in normal sleep. These changes have been linked to adverse cardiovascular effects [142] [143] [144] [145] 
Other Mechanisms Contributing to Sympathetic Dysregulation in OSA
Baroreflex Dysfunction
The baroreflex is also thought to play a role, albeit less important than the chemoreflex, in the sympathetic dysregulation that occurs in OSA [72, [147] [148] [149] [150] [151] . Patients with OSA have been noted to have decreased baroreceptor sensitivity [40•, 147] . Stretch of the carotid sinus and aortic arch baroreceptors increase cardiac vagal activity and decrease sympathetic activity. In OSA, however, since HR and BP both peak, the baroreceptors probably do not play a major role in mediating the autonomic response [146] , although they likely contribute to the post-apnea reduction in MSNA [34•]. Furthermore, chronic repetitive surges in blood pressure may lead to "resetting" of baroreceptors at a higher baseline blood pressure level. Such dysfunction of the baroreflex feedback system further contributes to chronic sympathetic activation, with subsequent chronic increase of blood pressure and heart rate. There may also be an indirect effect, in that input from the baroreceptors (in addition to that from the chemoreceptors) influences the amount of parasympathetic and sympathetic tonic activity upon which breathing can exert its influence [152] . In this context, the effects of baroreceptor stimulation on respiration [153] and the short-and long-term effects on BP [20•, 154, 155] have recently been described in greater detail. The role of low-pressure baroreceptors in the onset and progression of hypertension in OSA patients remains unclear.
Central Control
Changes in central neural control may also contribute to the sympathetic response to OSA [156, 157] . Increases in the central response to chronic intermittent hypoxia may partly explain the sensitization to acute hypoxia [30, 158] . A recent study in rats showed an increase in proinflammatory cytokines TNF-α and IL-1β as well as an increase in c-fos-positive neurons in the nucleus tractus solitarii [100] . Another study showed changes in delta fosB in central autonomic nuclei thought to contribute to the maladaptive changes causing chronically elevated sympathetic nerve activity in OSA [159, 160] . Furthermore, circulating catecholamines, as well as circulating angiotensin II, levels of which are elevated as a consequence of OSA-mediated increases in sympathetic activation, may directly cross the blood-brain barrier and thus directly stimulate sympathetic nuclei located in the hypothalamus and brainstem as well [161] . This positive feedback mechanism can substantially contribute to central elevation of sympathetic tonus, with all of its important hemodynamic, neurohumoral, and metabolic consequences [161, 162] .
Local Reflexes in the Heart
Normal inspiration results in increased HR and venous return that stimulates receptors in atria as well as caval and pulmonary veins, which then reduces cardiac vagal efferent activity. The effects on sympathetic activity, on the other hand, are less clear. Increased sympathetic cardiac efferent outflow has been noted in animal studies [163, 164] , while decreased MSNA, reduced forearm vascular resistance, and absence of tachycardia have been described in humans [165, 166] . A recent study showed blunted forearm resistance in response to voluntary apnea under experimental conditions in young healthy women but not in healthy postmenopausal women or men, implying that female sex hormones may dampen the effects of apneainduced sympathetic vasoconstriction [167] . These early data may explain why OSA is seen more frequently and tends to be more severe in men than in women. Further research is warranted to substantiate these findings.
Vascular Factors
More recent studies have focused on the role of vascular factors in the sympathoexcitatory response to OSA [161, 168] such as nocturnal endothelin release [169] , endothelial cell dysfunction [170, 171] , and apoptosis [172] . These adverse vascular effects, in fact, may be reversible with CPAP treatment [172, 173] . One study demonstrated that atorvastatin prevented vascular endothelial dysfunction, oxidative stress, and hypertension in response to intermittent hypoxia in rats [174] . If efficacy can be proven in human trials, statins may prove to be a useful adjunctive treatment strategy to help lower BP in patients with OSA.
Renin-Angiotensin System
There is increasing evidence implicating the renin-angiotensin system in the relationship between OSA and hypertension [175] [176] [177] . In rats, the effects of up-regulation of angiotensin AT1 receptors in the carotid body and oxidative stress have been shown to contribute to the increased sympathetic activity resulting from intermittent hypoxia [111, 178] . Also important is the link between the renin-angiotensin and sympathetic nervous systems. Sympathetic activation is the major factor stimulating release of renin from the juxtaglomerular system of the kidney. The subsequent creation of angiotensin II increases sympathetic tone by several different mechanisms at both central and peripheral levels. Tissue-specific production of catecholamines and angiotensin II induced by OSAmediated hypoxia also appear to be of clinical relevance, but this is beyond the scope of this article.
Other Factors
Sleep deprivation or short sleep duration [179, 180] and impaired exercise tolerance [181, 182] in the context of OSA may also contribute to the excess cardiovascular risk in OSA patients. Additional studies are needed to clarify the exact mechanisms through which these factors might exert their influence.
Conclusions
The chemoreflexes play an important part in regulation of ventilatory and cardiovascular responses. Sympathetic activity, which is sleep-stage-dependent in normal sleep, is proportional to the duration and severity of apnea and hypoxia in OSA. In addition, repeated arousals associated with respiratory events may result in sympathetic surges. Ultimately, sympathetic activity and pressor responses to hypoxia are increased in patients with OSA, not only in sleep but during wakefulness as well. Treatment of OSA appears to ameliorate this effect. The peripheral chemoreflex acting via the carotid bodies is thought to play a prominent role in this response, although mechanisms involving the baroreflex, vascular factors, and the renin-angiotensin system may also contribute. OSA patients appear to have increased peripheral chemosensitivity and tonic activation of the chemoreceptors not seen in weight-matched healthy controls. The response to hypoxia in OSA is exaggerated compared to non-OSA subjects exposed to hypoxia and is similar to that observed in early hypertension. The chemoreflex and altered sympathetic activity may explain the link between OSA and hypertension as well as other adverse cardiovascular consequences, but further study is needed, particularly in human subjects. There are some data suggesting that autonomic dysfunction may precede and lead to the development of hypertension. Methods to measure the chemoreflex contribution to sleep apnea have the potential to provide exciting new ways to predict the onset of hypertension and other cardiovascular outcomes in asymptomatic patients and thus target them for individualized treatment. 
